Anticoagulants Market Size and Share Analysis Report by Drug Type (Direct Oral Anticoagulants, Warfarin, Other Vitamin K, Heparins & Low Molecular Weight Heparin), Disease Indication (Heart Attack, Stroke, Deep Vein Thrombosis / Pulmonary Embolism, Mechanical Heart Valves), Route of Administration (Oral, Injection), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) - Global Industry Demand Forecast to 2030

Market Overview

The global anticoagulants market size in 2021 was $21,736.2 million, and it is expected to advance at a CAGR of 7.8% during the forecast period, to reach $42,893.4 million by 2030. These substances aid in the prevention of blood clots. They are given to those at an elevated danger of clotting, in order to lower their risks of developing severe illnesses, such as coronary heart disease and stroke. The increasing prevalence of deep vein thrombosis and coronary artery disease is likely to drive anticoagulant sales over the coming years, aided by the rising number of clinical trials and product launches.

Overview

Many companies provide these agents as a result of a large patient pool, greater government financing, and increasing demand for different treatments. Established participants are gaining large shares and carefully monitoring drug costs. Switching prices are minimal, as suppliers typically have long-term alliances, agreements, and partnerships with pharmaceutical companies. As the population of patients is growing and the occurrence of CVDs is rising, pharma firms have a large customer base. Due to the high prevalence of such illnesses, consumers are likely to purchase goods despite the high price.

Any new business seeking to enter the medicine manufacturing domain must obey the regulatory protocols of governments. Furthermore, the industry is defined by a substantial degree of brand recognition, which bodes well for the major firms since establishing a brand name is exceptionally hard for a startup. Furthermore, the expenditure on R&D and the stringency of the regulatory requirements the products need to meet are relatively high, thus making it difficult for a new firm to establish its operations.

Growth Opportunities in Emerging Economies

The increasing number of people in need of anticoagulation therapy is driving product launches in the global anticoagulants market. With new product introductions, the importance of distributors in remote areas is projected to rise. The customer base is expanding as the incidence of coronary heart disease and deep vein thrombosis rises.

Essentially, due to the rise in the population, increase in the prevalence of heart diseases, growth of economies, improvements in the diagnosis rate, and surge in the need for appropriate therapies, developing countries present a lucrative anticoagulants market growth potential. Furthermore, the expansion of the healthcare infrastructure and improvement in healthcare awareness are aiding the industry growth.

Explore more about this report - Request free sample pages

Drug Type

The direct oral anticoagulants (DOACs) category is a prominent revenue generator that will lead in product sales during 2021–2030 as well, owing to the rising DOAC adoption in emerging economies. Moreover, since they do not require frequent blood monitoring and can be administered safely at set doses, they are better and more effective than warfarin.

Thus, DOACs outperform warfarin in ischemic stroke prevention in individuals with nonvalvular atrial fibrillation (NVAF) and also reduce the number of significant bleeding episodes. This class of drugs is used to reduce the risk of stroke and systemic emboli, as well as to prevent deep vein thrombosis and pulmonary embolism.

Anticoagulants Mostly Used to Treat Heart Attack

These medicines are majorly given to patients suffering from or at a high risk of heart attacks. This is driven by the existence of top pharmaceutical and biotechnology businesses engaged in the creation of new therapeutics to help prevent myocardial infarctions. According to a government report, the U.S. has a heart attack every 40 seconds, and approximately 805,000 people in the country suffer from this condition each year.

Route of Administration

Oral anticoagulants will hold the largest revenue share, of more than 76%, in 2030. Oral administration is amongst the most-common ways of providing anticoagulation therapy. This practice is expanding as a result of new product launches and its ability to contribute to significant reduction of the risks associated with injections.

As per the analysis, in the coming years, the injection category is expected to develop significantly. These medicines can be administered via intravenous (IV) infusion or subcutaneous injection. When anticoagulation is required quickly, injectables are the preferred route of administration.

Distribution Channel

Retail pharmacies had the largest share in 2021 as they offer greater convenience in refilling prescription medications.

In the same way, the increase in the popularity of online pharmacy facilities due to the ease and comfort of ordering they provide to patients, especially the elderly, will drive the online pharmacies category at the highest CAGR during 2021–2030.

Regional Insights

North America accounted for the largest revenue share in 2021, and it will grow at a CAGR of 7.9% during 2021–2030, primarily on account of the rise in the prevalence of cardiovascular diseases. Recognizing the potential of the industry, prominent players are engaging in R&D activities to boost the number of pipeline medications. Furthermore, the developed healthcare system in the region is contributing to this growth.

The U.S. accounted for the larger revenue share in North America in 2021, owing to the high awareness about the utility of these medicines in disease management and the country's rising obesity incidence, which is already among the highest in the world.

The European region is also witnessing a rapidly growing demand for such drugs as it has a high prevalence of cardiovascular diseases and increasing investments in R&D in the pharmaceutical sector. The technologically advanced countries, such as the U.K., France, and Germany, will contribute to the expansion of the European sales of anticoagulants.

The APAC region is expected to register the highest CAGR, of more than 8%, during the forecast period due to the rising disposable income and a greater awareness of cardiac diseases in the region than before. The adoption of advanced drugs in the region's key countries and the growing status of heart-related diseases as the leading causes of mortality will drive the growth. Furthermore, the demand for these medicines has expanded dramatically as a result of national governments' financial help to modernize healthcare facilities and improve the quality of services.

The MEA region is also expanding rapidly due to a rise in the number of research companies and subsidiaries, as well as the increasing usage of modern anticoagulant drugs. Moreover, with the rising frequency of cardiovascular illnesses, the LATAM region will grow tremendously as well.

Competitive Landscape

The global anticoagulants market is predicted to continue growing in the coming years due to the presence of a large number of established players. Companies are active in product launches, mergers and acquisitions, and expansions, to boost their shares.

In February 2022, The U.S. FDA gave Bayer's oral Factor Xia inhibitor, Asundexian, which is in phase 2 trials, the fast-track classification.

In June 2021, the FDA approved Boehringer Ingelheim's dabigatran etexilate (Pradaxa) for children aged 3 months to less than 12 years who have a venous thromboembolism. The drug is given after at least five days of treatment with another blood thinner administered by injection.

Top Players in Anticoagulants Market Are:

• ASPEN PHARMACARE HOLDINGS LIMITED
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• DAIICHI SANKYO COMPANY LIMITED
• GlaxoSmithKline
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Sanofi

Market Size Breakdown by Segment

The study offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030.

Based on Drug Type

• Direct Oral Anticoagulants (DOACs)
• Warfarin
• Other Vitamin K
• "Heparins & Low Molecular Weight Heparin (LMWH) 

Based on Disease Indication

• Heart Attack
• Stroke
• Deep Vein Thrombosis (DVT)/ Pulmonary Embolism (PE)
• Mechanical Heart Valves (MHV)

Based on Route of Administration (ROA)

• Oral
• Injection

Based on Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • Australia
  • South Korea
  • India
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa